SNNLive – Antigen Express, Inc., a division of Generex Biotechnology – Video

Posted on by


SNNLive - Antigen Express, Inc., a division of Generex Biotechnology
SNNLive met with Dr. Eric von Hofe, President of Antigen Express, Inc., a division of Generex Biotechnology (OTCQB: GNBT) at the BioTech Showcase 2012 in San Francisco, CA. For more information:...

By: Stock NewsNow

Follow this link:
SNNLive - Antigen Express, Inc., a division of Generex Biotechnology - Video

Muthumani thooval tharam song …(Ajayan M.S ,Dept of Biotechnology ,CUSAT – Video

Posted on by


Muthumani thooval tharam song ...(Ajayan M.S ,Dept of Biotechnology ,CUSAT
My song:Muthumani Thooval tharam Movie:kauravar Singer :Ajayan M.S(Doctorate fellow in Biotechnology , CUSAT) Video shoot by Akhil by a low megapixel nikon c...

By: Ajayan Mannoor supran

Continued here:
Muthumani thooval tharam song ...(Ajayan M.S ,Dept of Biotechnology ,CUSAT - Video

Developing Agricultural 2014/sustainable agriculture/ Agricultural Technology/Agricultural Tve – Video

Posted on by


Developing Agricultural 2014/sustainable agriculture/ Agricultural Technology/Agricultural Tve
Agricultural biotechnology is a growing sector in North Carolina. With a great pipeline of research, vibrant agricultural biotechnology companies and a train. With the tools of biotechnology,...

By: Agricultural Tve

See the original post:
Developing Agricultural 2014/sustainable agriculture/ Agricultural Technology/Agricultural Tve - Video

Nano-biotechnology: carbon nanofibres as improved neural and orthopaedic implants – Video

Posted on by


Nano-biotechnology: carbon nanofibres as improved neural and orthopaedic implants
Nanotechnology celebrates 25 years in an interview with the author of one of the most cited and downloaded papers: #39;Nano-biotechnology: carbon nanofibres as ...

By: NanotechnologyVideo

Read this article:
Nano-biotechnology: carbon nanofibres as improved neural and orthopaedic implants - Video

3 Biotech – a SpringerOpen journal

Posted on by

3 Biotech is a quarterly, peer-reviewed open access journal published under the brand SpringerOpen.

Continuous Article Publishing (CAP)

3 Biotech will be moving to the Continuous Article Publishing (CAP) in 2016, in which newly accepted papers will be published online with volume and article numbers, shortly after receipt of authors proofs. This change will alleviate the significant backlog of accepted articles that are currently available online as "published ahead of time," but are awaiting formal publication with a volume, issue number and page numbers. To achieve a smooth transition to the CAP model, all papers that have been accepted after June 2015 have been held back and will be published with volume and article numbers from January 2016 onwards. We wish to apologize for this short delay in article processing during this important transition phase, which is designed to speed up the process from acceptance of articles to final publication without the need for articles to be placed in a "published ahead of time" waiting line. In addition, a formal rapid publication from 2016 will ensure that all articles in 3 Biotech are immediately available in indexing services for researchers.

3 Biotech publishes the results of the latest research related to the study and application of biotechnology to:

- Medicine and Biomedical Sciences - Agriculture - The Environment

The focus on these three technology sectors recognizes that complete Biotechnology applications often require a combination of techniques. 3 Biotech not only presents the latest developments in biotechnology but also addresses the problems and benefits of integrating a variety of techniques for a particular application. 3 Biotech will appeal to scientists and engineers in both academia and industry focused on the safe and efficient application of Biotechnology to Medicine, Agriculture and the Environment.

Articles from a huge variety of biotechnology applications are welcome including:

- Cancer and stem cell research - Genetic engineering and cloning - Bioremediation and biodegradation - Bioinformatics and system biology - Biomarkers and biosensors - Biodiversity and biodiscovery - Biorobotics and biotoxins - Analytical biotechnology and the human genome

3 Biotech accepts original and review articles as well as short research reports, protocols and methods, notes to the editor, letters to the editor and book reviews for publication. Up to date topical review articles will also be considered. All the manuscripts are peer-reviewed for scientific quality and acceptance.

NEW:

3Biotech hasrecently receivedits first Impact Factor and is nowcovered by a range of A&I services, including:

- Science Citation Index Expanded - Journal Citation Reports/Science Edition - Biological Abstracts - BIOSIS Previews

Best Paper Award: 3 Biotech is supported by King Abdulaziz City for Science and Technology (KACST) in Saudi Arabia. Every year KACST awards the best paper with the KACST Medal and $5,000. The editors of 3 Biotech have elected the best paper among those published in 2011-2012 and 2012-2013.

- The 2011-2012 winning paper is:

Nanocrystalline hydroxyapatite and zinc-doped hydroxyapatite as carrier material for controlled delivery of ciprofloxacin

Authors: G. Devanand Venkatasubbu and colleagues at Anna University, India.

- The 2012-2013winning paper is: Stress influenced increase in phenolic content and radical scavenging capacity of Rhodotorula glutinis CCY 20-2-26 Authors: Raj Kumar Salar and colleagues at Chaudhary Devi Lal University, India.

Related subjects Agriculture - Biomaterials - Biotechnology - Cancer Research - Cell Biology - Systems Biology and Bioinformatics

Journal Citation Reports, Thomson Reuters

Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed, PubMedCentral, EMBASE, Google Scholar, CAB International, AGRICOLA, Biological Abstracts, BIOSIS, CAB Abstracts, DOAJ, Global Health, OCLC, Summon by ProQuest

Originally posted here:
3 Biotech - a SpringerOpen journal

Should You Be Concerned About This Stock?: Cellect Biotechnology Ltd., (NASDAQ: APOP) – NasdaqNewsFeed

Posted on by

EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for its investors or shareholders, not only because of changes in profit, but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).

Cellect Biotechnology Ltd., belongs to Healthcare sector and Biotechnology industry. The companys Market capitalization is $32.60M with the total Outstanding Shares of 26. On 24-10-2019 (Thursday), APOP stock construct a change of 7.78 in a total of its share price and finished its trading at 2.91.

Profitability Ratios (ROE, ROA, ROI):

Looking into the profitability ratios of APOP stock, an investor will find its ROE, ROA, ROI standing at 0%, 0% and 0%, respectively. Return on assets (ROA) is a financial ratio that shows the percentage of profit a company earns about its overall resources. A performance measure used to estimate the efficiency of an investment or to compare the ability of some different investments. ROI measures the amount of return on an investment relative to the investments cost.

Earnings per Share Details of Cellect Biotechnology Ltd.:

The EPS of APOP is strolling at -0.85, measuring its EPS growth this year at 0%. As a result, the company has an EPS growth of 0% for the approaching year.

Given the significance of identifying companies that will make sure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

We cant have sufficient maintenance the once will always replicate the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to keep on to take effect as a result.

Analysts mean target price for the company is $12 while analysts mean suggestion is 0.

A beta factor is used to measure the volatility of the stock. The stock remained 30.17% volatile for the week and 14.57% for the month.

Historical Performance In The News:

Taking a look at the performance of Cellect Biotechnology Ltd. stock, an investor will come to know that the weekly performance for this stock is valued at 38.57%, resulting in a performance for the month at 20.28%.

Therefore, the stated figure displays a quarterly performance of 5.84%, bringing six-month performance to -35.9% and year to date performance of -72.29%.

P/S, P/E, P/C and P/B/ SMA50, SMA 200:

The price-to-sales is a valuation ratio that relates a companys stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a companys sales or taxes. As of now, APOP has a P/S, P/E and P/B values of 0, 0 and 4.21 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.

Its P/Cash valued at 0. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stocks price to its cash flow per share

What do you mean by simple moving average (SMA)?

A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for some time periods and then dividing this total by the number of time periods. Its distance from 20-days simple moving average is 29.2%, and its distance from 50 days simple moving average is 18.85% while it has a distance of -34.93% from the 200 days simple moving average. The companys distance from 52-week high price is 26% and while the current price is 26% from 52-week low price.

The rest is here:
Should You Be Concerned About This Stock?: Cellect Biotechnology Ltd., (NASDAQ: APOP) - NasdaqNewsFeed

Plandai Biotechnology, Inc. Releases Shareholder Newsletter With Accompanying Video – Video

Posted on by


Plandai Biotechnology, Inc. Releases Shareholder Newsletter With Accompanying Video
SEATTLE, WA, United States, via eTeligis Inc., 05/20/2014 - - Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health,...

By: Eteligis.com

The rest is here:
Plandai Biotechnology, Inc. Releases Shareholder Newsletter With Accompanying Video - Video